Parainfluenza virus (PIV) infection is well recognized as a cause of respiratory illness in children, ranging from mild upper respiratory tract symptoms to croup and pneumonia [1] . Almost all children encounter these viruses within the first few years after birth, but immunity is incomplete and reinfections occur throughout life [2, 3] . In immunocompetent adults, mild upper respiratory tract illness is the usual consequence of such reinfection, but lower respiratory tract infection in immunocompromised adults is increasingly accepted as a cause of serious morbidity and mor-tality, especially after the receipt of a hemopoietic stem cell transplant (SCT) [4] [5] [6] . PIV-induced pneumonia has a mortality of ∼40% in adult SCT patients, and the infecting virus is predominantly type 3 (PIV3) [6] . In 1995 and 1996, we experienced 2 consecutive outbreaks of PIV3 in the Hammersmith Hospital Bone Marrow Transplant Unit in which 5 of 13 infected SCT patients died [7] . This prompted a review of all cases since 1990 with the aim of assessing the value of early treatment with ribavirin following rapid laboratory detection of PIV3 by means of immunofluorescence (as opposed to the slower traditional method of virus isolation). Here we report the findings of this review.
PATIENTS AND METHODS

Patient population.
A total of 456 patients (396 adults and 60 children) received an SCT at the Hammersmith Hospital (London) from January 1990 through September 1996. Of these patients, 73 received an autologous transplant, either bone marrow or peripheral blood SCT; 223 were given bone marrow from a human leukocyte antigen (HLA)-identical sibling (one of whom was a twin); and the remaining 160 received bone marrow from an alternative donor, of whom 12 were HLA-mismatched family members and 148 were volunteer unrelated donors.
Patients with PIV infection were identified by a review of the database in the Diagnostic Virology Laboratory at the Hammersmith Hospital. The case notes of these patients were examined with respect to symptoms, treatment, and outcome.
Definitions. Upper respiratory tract illness was defined as cough, coryza, or rhinorrhea with or without fever, but without hypoxia or signs on the chest radiograph. Lower respiratory tract illness was defined as signs or symptoms of pulmonary infection or compromise-for instance, rales, wheezes, dyspnea, or shortness of breath on exertion, changes on chest radiograph (such as shadowing or nodular infiltrates), and low oxygen saturation. Community-acquired infection was defined as an infection in which PIV3 was recovered from the patient within 4 days of admission to the hospital, because the incubation period for PIV3 is 2-3 days [8] . Nosocomially acquired infection was defined as an infection in which PIV3 was recovered from a patient 14 days after admission.
Methods of transplantation. All patients were given conditioning with chemotherapy, radiotherapy, or both, as appropriate for their underlying disease and the indication for SCT. In addition, recipients of allogeneic stem cell transplants were given immunoprophylaxis against graft versus host disease [9] [10] [11] . Before 1995, patients receiving bone marrow from a volunteer unrelated donor or HLA-mismatched family donor underwent in vivo T cell depletion with the monoclonal antibody Campath-1G; after 1995, Campath-1G was replaced with Campath-1H. Acyclovir was given as prophylaxis against disease caused by herpes simplex virus. Ganciclovir was used either preemptively or prophylactically for the prevention of human cytomegalovirus disease [12, 13] . Isolation measures included reverse barrier nursing and standard hygenic procedures. Most of the sibling SCT recipients and all of the volunteer unrelated donor SCT patients were nursed in, but not confined to, single rooms with positive pressure filtration devices. Autologous SCT patients were sometimes accommodated in a 4-bed bay.
Laboratory diagnosis of PIV3 infection. Respiratory samples (throat gargle, sputum, nasopharyngeal aspirate, or bronchoalveolar lavage) from SCT recipients with symptoms of upper respiratory tract infection, lower respiratory tract infection, or both were submitted to the Diagnostic Virology Laboratory. Diagnosis of PIV3 infection was made by means of direct immunofluorescence of samples with fluorescein isothiocyanateconjugated PIV3-specific monoclonal antibody (Dako Diagnostics), isolation of PIV3 in primary rhesus monkey kidney cells (European Cell Culture Collection), or both, and identification was performed by means of hemadsorption and fluorescence. PIV3 infection occurred throughout the year, with the lowest incidence (2 [8.3%] of 24) in the first quarter of the year and the highest (11 [46%] of 24) in the third quarter (figure 1); there were no new infections found in December, January, or February during the period of our retrospective survey. Overall, nosocomial infection accounted for 16 (67%) of 24 cases (figure 1). The proportion was even higher (11 [79%] of 14) in 1995 and 1996, when 2 consecutive PIV3 outbreaks were caused by person-to-person transmission within the SCT unit at the Hammersmith Hospital [7] . The first outbreak was protracted and lasted from July through November 1995; it involved 7 SCT patients. The second outbreak lasted for a month in August 1996 and involved 6 SCT patients; details of the molecular epidemiology and measures taken for infection control of these outbreaks are given elsewhere [7] .
Clinical presentation and diagnosis of PIV3 infection. Of 24 total patients infected with PIV3, 10 had upper respiratory tract infection alone, but the other 14 developed signs of lower respiratory tract infection. Upper respiratory tract PIV3 infection was mostly characterized by cough, coryza, and fever, but in 2 patients, there was only rhinorrhea. Three patients also had paranasal sinusitis [14] . In the 14 patients with symptoms of lower respiratory tract disease, dyspnea was the main complaint, but 10 patients also had radiological evidence of pneumonia. Low oxygen saturation was frequent and was the only abnormal finding in 1 patient. There was no difference in neutrophil or lymphocyte counts between those with upper and those with lower respiratory tract infections (data not shown).
Of the 14 patients with lower respiratory tract infections, 2 patients had lower respiratory tract disease at first presentation, whereas in the other 12 patients, the symptoms progressed from those of an original upper respiratory tract infection. Regarding the timing of diagnosis of PIV3 infection, in 22 of the 24 patients, the date of onset of illness was recorded. It could therefore be calculated that a median delay of 4 days elapsed before the diagnosis was established by means of laboratory tests (range, 0-22 days). By the time of laboratory diagnosis, 13 patients already had signs of lower respiratory tract infection.
The diagnosis of PIV3 infection was established by means of immunofluorescence, culture, or both. In 20 (83%) of the 24 patients, the result of an immunofluorescence test (on 11 bronchoalveolar lavages, 8 sputa, and 1 nasopharyngeal aspirate) was positive, whereas in 4 of the 24 patients, the diagnosis was delayed until PIV3 was isolated in culture (1 bronchoalveolar lavage, 1 sputum, 1 nasopharyngeal aspirate, and 1 throat gargle). Immunofluorescence was more sensitive than culture because virus was grown for only 10 patients (5 bronchoalveolar lavages, 3 sputa, 1 throat gargle, and 1 nasopharyngeal aspirate). Immunofluorescence was also more rapid than culture; the immunofluorescence result was available the day the specimen was obtained, whereas the mean time taken to isolate PIV3 in culture was 11.8 days (range, 4-22 days).
Treatment and outcome of PIV3 infection. ) SCT patients. Similarly, the P p 1.0 mortality associated with lower respiratory tract disease was equally high after the receipt of alternative donor SCT (6 [86%] of 7 patients), sibling SCT (1 [50%] of 2 patients), and autologous SCT (1 [100%] of 1 patient). Regarding concurrent infections, 5 of the 8 patients who died had other serious infections, including Aspergillus fumigatus (2 patients), cytomegalovirus (2 patients), and Pneumocystis carinii (1 patient, whose case has been described in full elsewhere [15] ). A. fumigatus was found in only 2 of the other 6 patients with lower respiratory tract infections who survived (table 2) . Overall, of the 14 patients with pneumonia, PIV3 was the only pathogen found in 7 patients. None of the patients who died underwent postmortem examination. Table 3 shows the relationship of outcome of PIV3 infection to time after transplant. PIV3 infection was diagnosed at a [15] ; and 1 patient was also infected with A. fumigatus. median of 50 days after the receipt of an SCT (range, 10-244 days). Twenty (83%) of the 24 patients developed PIV3 infections within 100 days of transplantation. Of these 20 patients, 10 had an uncomplicated upper respiratory tract infection, and all survived the episode. In the remaining 10 patients, PIV3 infection was associated with lower respiratory tract disease, and 8 (80%) of these 10 died. The course of the infection in the 8 patients who died varied from rapid (1-2 weeks) to insidious (6 weeks and 4 months). The remaining 4 patients (1 recipient of alternative donor SCT and 3 recipients of sibling SCTs) developed PIV3 infection together with lower respiratory tract disease 1100 days after transplant; all 4 survived the episode. Although duration of PIV3 shedding was not systematically assessed, 9 of the 24 PIV3-infected patients had the virus detected by means of immunofluorescence, culture, or both in 11 sample (PIV3 shedding by 6 of these patients has been previously described [7] ). The median duration of shedding was 23 days (range, 5-121 days), and all patients were symptomatic. Protracted virus shedding was found in 1 patient with upper respiratory tract disease (111 days) and 1 patient with lower respiratory tract disease (121 days).
Considering the effect of ribavirin treatment on PIV3 shedding, 18 of the 24 patients received at least 1 course of ribavirin for 7-10 days, and the median duration of shedding of PIV3 was 26 days (range, 8-121 days). Some patients received repeated courses of ribavirin because of persistent shedding of PIV3 (data not shown). In particular, 1 patient received 3 courses (in total, 103 days) of aerosolized ribavirin as well as iv ribavirin just before his death but continued to shed virus, as detected by means of both immunofluorescence and virus isolation, despite therapy.
Ribavirin therapy was started on the day of diagnosis for all patients, and the median delay from date of onset of illness was 3 days (range, 0-17 days). This median delay of 3 days was the same in those who died and those who survived. As shown in table 4, 8 (80%) of 10 patients with upper respiratory tract infection were given ribavirin, and none of the 10 died. A total of 10 (71%) of the 14 patients with lower respiratory tract symptoms received ribavirin, but 6 (75%) of 8 patients who received ribavirin within 100 days of transplantation died (table 4), including the only patient who was treated before the infection had progressed to the lower respiratory tract. In the other 9 patients, pneumonia was already established at the time that ribavirin therapy was started, although none were in respiratory distress. Of the 6 treated patients who died, 3 had concurrent infections, whereas 2 (50%) of 4 patients in the untreated group died; both had concurrent infections (table 4) .
DISCUSSION
This report describes the retrospective identification of PIV infection in 26 SCT recipients over a 6-year period. With regard to the clinical spectrum, our findings are similar to those of the 2 previous large studies [5, 6] : the frequency of infection was the same, the majority of PIV infections were due to PIV3, the incidence of lower respiratory tract disease and mortality was high, and deaths occurred only in those patients who were first infected within 100 days of receipt of an SCT (table 2) . As reported elsewhere [5, 6] , many patients who died had concurrent infections. It was particularly difficult in the present series to know the precise cause of death because none of the patients had postmortem examinations, although PIV3 was the only respiratory pathogen identified before death in 3 patients. However, PIV3 giant cell pneumonia has been reported in immunodeficient patients [16] , and Lewis et al. [6] documented PIV3 invasion of lung in biopsy and necropsy specimens of SCT recipients, some of whom had concurrent infections as well. There is also a case report suggesting dissemination of PIV3 beyond the respiratory tract in an immunocompromised patient [17] .
PIV3 infections in England and Wales are seasonal; they occur mostly from April through August, with the lowest numbers being reported during the winter (December-March) [18] . This pattern was reflected by the infection in the patients we studied (figure 1), except in 1995, when there was an autumn outbreak in the Bone Marrow Transplant Unit after the community outbreak had ceased; protracted shedding of PIV3 by 1 patient was identified as the source of nosocomial transmission [7] . Such nosocomial transmission is a serious problem; in the present survey, two-thirds of patients became infected while in the hospital ( figure 1) .
Prevention of nosocomial transmission requires rapid, early identification of PIV3 infection so that patients may be isolated. The 2 previous studies of PIV infection after the receipt of an SCT [5, 6] relied on isolation of PIV3 from respiratory specimens in tissue culture with a consequent delay in diagnosis of ∼9 days after sampling [5] . In contrast, our main diagnostic tool was immunofluorescence testing, which is rapid, very sensitive, and specific [19] [20] [21] . In the present study, 20 (83%) of 24 PIV3 infections were detected by means of immunofluorescence, as compared with 10 (42%) of 24 that were detected by means of culture. This insensitivity of culture for diagnosis of PIV3 infection after SCT has also been reported by Wendt et al. [5] . Of equal significance in our series, culture of PIV3 took ∼12 days to perform, whereas an immunofluorescence result was available within 1 day, thus reducing the time to diagnosis by 11 days. These rapid results helped with infection control during the 1995 and 1996 outbreaks in the Bone Marrow Unit [7] . Such timely results also meant that ribavirin therapy was started early after the onset of symptoms. This is especially significant because progression of PIV3 infection proceeded very rapidly in the heavily immunocompromised SCT patients; 13 patients had already developed signs of pneumonia at the time of rapid diagnosis of PIV3 infection, and any further delay would have compromised early ribavirin treatment.
The most important aspect of the present findings concerns the effectiveness of such early therapy. Ribavirin has been shown to be active against PIV3 infection in vitro and in vivo [22] , but its efficacy in humans remains to be established because there have been no controlled clinical trials. In 1 of the only 2 large series [5] , 9 (33%) of 27 SCT patients infected with PIV3 were treated with aerosolized ribavirin, although without benefit, in terms of survival. However, ribavirin treatment was started late at a median of 11 days after onset of symptoms after culture-based diagnosis. In the only other large series [6] , 5 (8%) of 61 patients were given aerosolized ribavirin, and the 3 in whom treatment was initiated in the early stage of pneumonia survived. The delay between onset of symptoms and treatment was not stated, but diagnosis was again made on the basis of culture results, and it was not clear whether the good outcomes were coincidental or whether ribavirin therapy had actually altered the natural history of the infections.
In our series, ribavirin was used in a high proportion of case patients: 18 (75%) of 24 patients received ribavirin (table 4) . The median delay from onset of illness was just 3 days, but despite this early treatment, we could not discern an improvement in outcome; mortality was very high within the first 100 days after the receipt of an SCT, and all 3 patients in this period in whom the only pathogen identified was PIV3 and who developed pneumonia died. It also seems improbable that early treatment prevented progression of disease from upper to lower respiratory tract, because the proportion of patients with uncomplicated infection is similar to that reported in the 2 previous series in which the majority of patients did not receive ribavirin [5, 6] . Moreover, 1 patient in our series started therapy with ribavirin while experiencing upper respiratory tract symptoms alone, but the patient's condition subsequently progressed to pneumonia. Finally, there was no evidence that ribavirin therapy was effective in clearing PIV3; in 2 patients who received treatment, the course of infection was prolonged. This is not unexpected because ribavirin is virustatic, not virucidal [23] .
In summary, rapid diagnosis of PIV3 infection made on the basis of immunofluorescence results allowed early ribavirin treatment of respiratory tract infection in SCT patients. It also provided a timely warning of the necessity for patient isolation to avoid nosocomial spread. However, despite ribavirin therapy, the outcome was not modified in patients with lower respiratory tract disease. This highlights the need for prospective screening by use of very sensitive tests, such as reverse transcriptase-PCR, to allow the earliest possible intervention for the avoidance of nosocomial transmission and the development of effective therapeutic strategies that use properly controlled randomized trials.
